Facet-Joint Injection Market Report 2026

The facet-joint injection market size has grown strongly in recent years. It will grow from $2.97 billion in 2025 to $3.18 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to spinal degeneration prevalence, arthritis incidence, pain management awareness, corticosteroid use, outpatient procedure growth.

The facet-joint injection market size is expected to see strong growth in the next few years. It will grow to $4.1 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to aging population, minimally invasive preference, chronic pain prevalence, ambulatory care expansion, imaging-guided procedures. Major trends in the forecast period include rising demand for minimally invasive pain procedures, increased use in chronic back pain management, growth of outpatient pain clinics, adoption of image-guided injection techniques, expansion of ambulatory surgical centers.

The rising prevalence of spinal diseases and chronic back pain is expected to drive the growth of the facet-joint injection market in the coming years. Spinal diseases and chronic back pain refer to long-term conditions affecting the spine, including disc degeneration, arthritis, and nerve compression, which lead to persistent discomfort, limited mobility, and reduced quality of life. The prevalence of these conditions is increasing due to sedentary lifestyles and poor posture habits, prompting individuals to seek effective, minimally disruptive treatments that relieve discomfort and restore functional movement. Facet-joint injections help manage spinal diseases and chronic back pain by reducing inflammation and pain in the spine, providing targeted relief for affected individuals. For instance, in May 2023, according to Spinal Cord Inc., a US-based non-profit resource center, approximately 18,000 new spinal cord injury cases are reported annually in the United States, with an estimated 302,000 individuals currently living with spinal cord injuries nationwide. Therefore, the rising prevalence of spinal diseases and chronic back pain is driving the growth of the facet-joint injection market.

The growing demand for minimally invasive procedures is also expected to support the growth of the facet-joint injection market. Minimally invasive procedures are medical interventions performed through small incisions or without extensive surgical cuts, offering faster recovery times and reduced post-operative pain. Facet-joint injections complement minimally invasive procedures by delivering precise pain relief and diagnostic accuracy without requiring major surgery. For instance, in 2023, the American Society of Plastic Surgeons, a US-based specialty organization, reported that the total number of minimally invasive cosmetic procedures increased from 23.7 million in 2022 to 25.4 million in 2023. Therefore, the rising demand for minimally invasive procedures is contributing to the growth of the facet-joint injection market.

Major companies in the facet-joint injection market are focusing on developing innovative products, such as facet fusion systems, to provide longer-lasting relief and improve treatment outcomes. Facet fusion systems are medical devices designed to stabilize and fuse the facet joints of the spine by promoting bone growth between adjacent vertebrae. For instance, in March 2025, Aurora Spine Corporation, a US-based medical device company, announced that its AEROTM Facet Fusion System received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system integrates titanium plasma spray coating to enhance osseointegration and fusion potential, supports multiple implant sizes to accommodate varied patient anatomies, and offers radiolucent instrumentation to improve intraoperative visibility. These features collectively aim to enhance procedural efficiency and long-term outcomes in treating chronic back pain caused by facet joint disorders.

Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation.

North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the facet-joint injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs in the facet-joint injection market by impacting imports of corticosteroids, hyaluronic acid, anesthetics, and sterile injection devices. Lumbar and cervical facet joint procedures are most affected, particularly in North America and Asia-Pacific where many injectable materials are imported. Hospitals and specialty clinics face rising procedure costs. Positively, tariffs are promoting local manufacturing of injectable drugs and interventional pain management supplies.

The facet-joint injection market research report is one of a series of new reports that provides facet-joint injection market statistics, including facet-joint injection industry global market size, regional shares, competitors with a facet-joint injection market share, detailed facet-joint injection market segments, market trends and opportunities, and any further data you may need to thrive in the facet-joint injection industry. This facet-joint injection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A facet joint injection is a minimally invasive procedure used to diagnose or treat pain from the facet joints, which are small joints connecting each pair of vertebrae in the spine. The injection usually contains a combination of a local anesthetic, to numb the area, and a corticosteroid, to reduce inflammation. It is commonly employed to relieve chronic neck, back, or thoracic pain caused by arthritis or spinal degeneration.

The main types of facet joint injections include corticosteroids, local anesthetics, hyaluronic acid, and others. Corticosteroids are steroid hormones used to reduce inflammation and suppress the immune system. Applications include cervical, thoracic, and lumbar facet joints, as well as general facet joint injections. These injections are used by end-users such as hospitals, ambulatory surgical centers, specialty clinics, and others.

The facet-joint injection market consists of revenues earned by entities through medication management, rehabilitation and psychological counseling, and interventional procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The facet-joint injection market also includes of sales of injection kits, imaging guidance systems, patient monitoring devices, and pain-relieving medications. Values in this market are ‘factory gate’ values, meaning the value of goods sold by the manufacturers or creators, whether to other companies (like distributors, clinics, and hospitals) or directly to end users. The value of goods in this market also includes related services provided by the creators, such as training or support for the use of injection products.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.